Link between intracellular pathogens and cardiovascular diseases

Clinical Microbiology and Infection

Volumn 4, Issue SUPPL. 4, 1998, Pages 4S33-4S36

  Gurfinkel, Enrique ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN FAVALORO   (Argentina)

Author keywords

Acute coronary syndromes; Angina; Atherosclerosis; Chlamydia pneumoniae; Coronary heart disease; Roxithromycin

Indexed keywords

CYTOKINE; MACROLIDE; ROXITHROMYCIN;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY ATHEROSCLEROSIS; CYTOMEGALOVIRUS; ELECTRON MICROSCOPY; HELICOBACTER PYLORI; HUMAN; IMMUNOCYTOCHEMISTRY; INFLAMMATORY CELL; MACROPHAGE; MONOCYTE; MYCOPLASMA PNEUMONIAE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; T LYMPHOCYTE;

ANGINA; CHLAMYDIA; CHLAMYDOPHILA PNEUMONIAE; CYTOMEGALOVIRUS; HELICOBACTER PYLORI; MYCOPLASMA PNEUMONIAE;

EID: 0031743887     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.1998.tb00701.x     Document Type: Conference Paper

References (42)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s Nature 1993; 362: 801-8.
2. Gerrity RG. The role of the monocyte in atherogenesis. Am J Pathol 1981; 103: 181-90.
3. Mazzone A, De Servi S, Ricvutti G, et al. Increased expression of neutrophil and monocyte adhesion molecules in unstable coronary artery disease. Circulation 1993; 88: 358-60.
4. van der Wal AC, Becker A, van der Loos CM, Das PK. Site of intimai rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994; 90: 1662-8.
5. Fuster V, Badimon L, Badimon JJ, Chesbro JH. The pathogenesis of the coronary artery disease and the acute coronary syndromes: Part 1 and 2. N Engl J Med 1992; 326: 242-50, 310-18.
6. Kruskal JB, Commerford PJ, Franks JJ, Kirsch RE. Fibrin and fibrinogen-related antigens in patients with stable and unstable artery disease. N Engl J Med 1987; 317: 1361-5.
7. Theroux P, Latour JG, Leger-Gautier C, De Lara J. Fibrinopeptide A plasma levels and platelet factor 4 levels in unstable angina pectoris. Circulation 1987; 75: 156-62
8. Eisenberg PR, Sherman LA, Schectman K, Perez J, Sobel BE, Jaffe AS. Fibrinopeptide A: a marker of acute coronary thrombosis. Circulation 1985; 71: 912-18.
9. Teitel JM, Bauer KA, Lau HK, Rosenberg RD. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/prothrombin fragment 1+2 fragment and thrombin/ antithrombin complex Blood 1982; 59: 1086-97.
10. Gurfinkel E, Altman R, Rouvier J, Scazziota A, Mautner B. Significance of thrombosis and thrombolysis in silent myocardial ischaemia Br Heart J 1994; 71: 151-5.
11. Krucoff MW, Wagner NB, Pope JE, et al. The portable programmable microprocessor-driven real-time 12-lead electrocardiographic monitor: preliminary report of a new device for the non-invasive detection of successful reperfusion or silent coronary reocclusion. Am J Cardiol 1990; 65: 143-8.
12. Gurfinkel E, Bozovich G, Mejaíl I, Cerdá M, Oxilia A, Mautner B. Time significance of acute thrombotic reactant markers in patients with and without silent myocardial ischemia and overt unstable angina. Am J Cardiol 1995; 76: 121-4.
13. Braunwald, E, Mark DB, Jones RH, et al. Unstable angina: diagnosis and management. Clinical Practice Guideline No. 10. Rockville, MD Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute, Public Health Service, US Department of Health and Human Services, 1994: 154.
14. Lewis HDJ, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983, 309. 396-9
15. Theroux P, Waters D, Qiu S, et al. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993; 88: 2045-9
16. Wallentin L, RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827-30.
17. Oler A, Whooley MA, Older J, et al. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. JAMA 1996, 276: 811-15.
18. Theroux P, Quimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988, 319: 1105-11.
19. Cohen M, Adams P, Parry G, et al. Combination antithrombotic therapy in unstable rest angina and non Q-wave infarction in non prior aspirin users. Circulation 1994; 89: 81-8.
20. Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a standard care nomogram. Ann Intern Med 1993; 119: 874-7.
21. Gurfinkel E, Manos E, Mejail I et al. Regular heparin use in a trial of unstable angina nomogram of infusion and APTT target rime in relation to major bleeding. Thromb Haemost 1995; 73(suppl): 981.
22. The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q wave myocardial infarction. Circulation 1884; 89: 1545-56.
23. Theroux P, Waters DD, Lam J, Junmau M, McCanse J. Reactivation of unstable angina following discontinuation of heparin. N Engl J Med 1992; 327: 141-5.
24. Granger CB, Miller JM, Bovill EG, et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 1995; 91: 1929-35.
25. Sylven C, Hagerman H, Karlsberg KE, et al. Platelet and leukocyte activation after myocardial infarction. Eur Heart J 1995; 16: 1800-6.
26. Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of acute unstable angina and silent ischaemia. J Am Coll Cardiol 1995; 26: 313-18.
27. Salzman EW. Low molecular weight heparin. Is small beautiful? N Engl J Med 1986; 315: 957-9.
28. Hirsh J. Low molecular weight heparin. Thromb Haemost 1993; 70: 204-7.
29. Linnanmaki E, Leinonen M, Mattila K, Nieminen MS, Valtonen V, Saikku P Chlamydia pneumoniae-specific circulating immune complexes in patients with chronic coronary heart disease. Circulation 1993; 87: 1130-4.
30. Saikku P, Leinonen M, Mattila K et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; 11: 983-5.
31. Thom DH, Grayston JT, Siscovick DS, Wang SP, Weiss NS, Dalling JR. An association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA 1992; 268: 68-72.
32. Muhlstein JB, Hammond EH, Cariquist JF, et al. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerosis versus other forms of cardiovascular disease. J Am Coll Cardiol 1996, 27. 1555-61.
33. Jackson LA, Campbell LA, Kuo CC, Grayston JT. Detection of Chlamydia pneumoniae in atheroma specimens. J Infect Dis 1996; 174: 893-6.
34. Gurfinkel E, Duronto E, Cerda M, et al Patients with unstable angina related with C reactive protein and Chlamydia pneumoniae infection. Eur Heart J 1996; 17(suppl): 578.
35. Rathbone B, Martin D, Stephens J, Thompson JR, Samani NJ. Helicobacter pylori seropositivity in subjects with acute myocardial infarction. Heart 1996; 76: 308-11.
36. Niemela S, Karttunen T, Korhonen T, et al Could Helicobacter pylori infection increase the risk of coronary heart disease by modifying serum lipid concentrations? Heart 1996; 75: 573-5.
37. Scragg RKR, Fraser A, Metcalf PA. Helicobacter pylori seropositivity and cardiovascular risk factors in a multicultural workforce. J Epidemiol Community Health 1996; 50: 578-9
38. Epstein SE, Speir E, Zhou YF, Guetta E, Leon M, Finkel T. The role of infection in restenosis and atherosclerosis: focus on cytomegalovirus. Lancet 1996; 348(suppl I): S13-17.
39. Patel P, Mendall MA, Carrington D, et al. Association of Helicobacter pylori and Chlamydia pneumoniae infection with coronary heart disease and cardiovascular risk factors. Br Med J 1995; 311: 711-14.
40. Blasi F, Denti F, Erba M, et al. Detection of Chlamydia pneumoniae but not Helicobacter pylori in atherosclerotic plaques of aortic aneurysms. J Clin Microb 1996; 34: 2766-9.
41. Gurfinkel E, Raimondi E, Manos E, Dos Santos A, Haas E, Mautner B. Potential interaction between inflammation and the human leukocyte antigens system in the setting of non-Q-wave coronary syndromes. PR Health Sciences Journal 1997 (suppl A), 16: A-51
42. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B, for the Roxis Study Group Randomized trial of roxithromycin in non-Q-wave coronary syndromes: Roxis Pilot Study. Lancet 1997; 350 404-7.